«Alternative» drugs for obesity treatment: Myth and reality;Tratamientos «alternativos» de la obesidad: Mito y realidad

Medicina Clinica

Volumn 121, Issue 13, 2003, Pages 500-510

  De Villar, G P Noemí ^a   Loria, Viviana ^a   Monereo, Susana ^a  

^a Soc Espanola de Endocrinol y Nutr   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; CYNARA SCOLYMUS EXTRACT; DIURETIC AGENT; EPHEDRA EXTRACT; EPIGALLOCATECHIN; EXOLISE; HERBACEOUS AGENT; ISPAGULA; MAGNESIUM; RHAMNUS EXTRACT; SEDATIVE AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; VALERIAN; VITAMIN;

ARTICHOKE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG APPROVAL; DYSLIPIDEMIA; EATING HABIT; EQUISETUM; FUCUS; GARCINIA CAMBOGIA; HOMEOPATHY; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; LIFESTYLE; OBESITY; PHYSICAL ACTIVITY; PHYTOTHERAPY; PINEAPPLE; REVIEW; RHAMNUS; RISK FACTOR; TEA;

EID: 0242636061     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13053141     Document Type: Review

References (77)

1. WHO. Obesity: preventing and managing the global epidemics. Geneve: WHO, 1998; p. 161-238.
2. Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagnon YC, Bouchard C. The human obesity gene map: the 2001 update. Obes Res 2002;10:196-243.
3. Methods for voluntary weight loss and control: NIH Technology Assessment Conference Panel. Consensus Development Conference 30 March to 1 April 1992. Ann Intern Med 1993;119:764-70.
4. McCarron DA, Reusser ME. Reducing cardiovascular disease risk with diet. Obes Res 2001;9 (Suppl 4):335-40.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
6. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
7. Cummings S, Parham ES, Strain GW. Position of the American Dietetic Association: weight management. J Am Diet Assoc 2002;102:145-55.
8. SEEDO. Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2000;115:587-97.
9. Estudio prospectivo Delphi. Costes sociales y económicos de la obesidad y sus patologías asociadas (hipertensión, hiperlipemia y diabetes). Los tratamientos del futuro y el coste-beneficio generado por su aplicación en el horizonte del año 2005 en España. Madrid: NILO Industria Gráfica S.A., 1999.
10. Real Decreto 2685/1976, de 16 de octubre, (BOE 26-XI-76) y sus modificaciones: R.D. 1444/2000 de 31 de julio (BOE 1-VIII-00). R.D. 431/99, de 12 de marzo. (BOE 13.III.99). R.D. 1809/1991 de 13 de diciembre (BOE 25-XII-91). Orden de 30 de abril de 1997, por la que se regulan los tratamientos dietoterápicos complejos. R.D. 1091/2000 de 9 de junio (BOE 10-VI-00).
11. Real Decreto 1430/1997 de 15 de septiembre (BOE 24-XII-97).
12. Real Decreto 72/1998 de 23 enero (BOE 4-II-98), modificado por R.D. 1446/2000 de 31 de julio (BOE 1-VIII-00).
13. Real Decreto 2730/1981. R.D. 1416/1994 de junio.
14. Consejo General de Colegios Oficiales de Farmacéuticos. Plantas medicinales en la farmacia. Disponible en: www.cof.es
15. Real Decreto 767/1993 de mayo.
16. Real Decreto 431/1999 del 12 de marzo, por la que se modifica la reglamentación técnico-sanitaria para la elaboración, circulación y comercio de preparados alimenticios para regimenes dietéticos y/o especiales, aprobada por el Real Decreto 2685/1976 de 16 de octubre.
17. Orden 10 de diciembre de 1985 por la que se regulan los mensajes publicitarios referidos a medicamentos y determinados productos sanitarios BOE 302/1985; p 39894.
18. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al, for the STORM Study Group. Effect of sibutramine on weight manteinance after weight loss: a randomised trial. Lancet 2000;356:2119-25.
19. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61
20. Davidson MH, Hauptmann J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for two years with orlistat. JAMA 1999;281:235-42.
21. Dujovne CA, Zavoral JH, Rowe E, Mendel CM; The Silbutramine Study Group Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2000;142:489-97
22. McNeely W, Benfield P. Orlistat. Drug 998;56:241-9.
23. Hauptman J. Orlistat: selective inhibition of caloric absorption can affect long-term body weight. Endocrine 2000;13:201-6.
24. Hansen DL, Toubron S, Stock MJ, Mcdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6.
25. Sharma AM. Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat Metab Disord 2001;25(Suppl 4):S20-3.
26. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, Bascil-Tutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55.
27. Chantre P, Liaron D. Recent effects of green tea extract AR-25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 2002;9:3-8.
28. Juhel C, Armand M, Pafumi Y, Rosier C, Vandermander J, Lairon D. Green tea extract (AR 25R) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro J Nutritional Biochemistry. 2000;10:45-51.
29. Orden de 14 de febrero de 1997 por la que se establecen determinados requisitos en la prescripción y dispensación de fórmulas magistrales y preparados oficinales para tratamientos peculiares. BOE de 26 de febrero de 1997.
30. De Villar NPG, Koning F, Loria V, Monereo S, Gómez-Enterrí a P. La Obesidad y la SEEN: Centro de Información de la Obesidad. Actas del 44 Congreso de la Sociedad Española de Endocrinología y Nutrición. Alicante, mayo-2002.
31. Montini M, Levoni P, Ongaro A, Pagani G. Controlled aplication of cynarin in the treatment of hyiperlipemic syndrome. Observations in 60 cases. Arzneimittelforschung 1975;25:1311-4.
32. Lemus I, Garcia R, Erazo S, Peña R, Parada M, Fuenzalida M. Diuretic activity of an equisetum bogotense tea (Platero Herb): evaluation in healthy volunteers. Jethnopharmacol 1996;54:55-8.
33. Infito: Centro de Investigación sobre Fitoterapia. Consejos dietéticos y plantas medicinales para ei tratamiento del sobrepeso y la obesidad en oficina de farmacia. Madrid: Centro de Investigación sobre Fitoterapia (INFITO), 2002.
34. Girola M, de Bernardi M, Contos S, Tripodi S, Ventura P, Cuarino C, et al. Dose effect un lid-lowering activity of a new dietary integrator (chitosan, garcinia cambogia extract and chrome). Acta Toxicol 1996;17:25-40.
35. Heyimsfield SB, Allison DB, Vaselli JR, Pietrobelli A, Green Field D, Núñez C. Garcinia cambogia (hidroxycitric acid) as a potencial antiobesity agent: a randomized controlled trial. JAMA 1998;280:1596-600.
36. Mattes RD, Bormann L. Effects of hydroxcitric acid on appetitive variables. Physiolbehar 2000;71:87-94.
37. Cairella M, Marchin G. Ve dell'attivita del glucomanano su alcuin parametri metabolici e sulla sensazione di sazieta in pazienti con sovrappeso ed obesitá. La Clínica Terapéutica 1995;146:269-74.
38. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang - Guaraná for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Dis 2001;24:316-24.
39. Englertf. Harnichsfeger G. Diuretic action of aqueous ortosiphon extract in rats. Planta Med 1992;54:239-46.
40. Bruneton J. Farmacognosia. Fitoquimica. En: Plantas medicinales. 2.a ed. Zaragoza: Acribia, 2001; p. 250-1.
41. Turnbull WH, Thomas HG. The effect of a plantago ovata seeds containing preparation on appetite variables, nutrient and energy intake. Int J Obes Relat Metab Dis 1995;19:338-42.
42. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, et al. Efficacy of a green tea extract rich in catechin poliphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999;70:1040-5.
43. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000;141:980-7.
44. Liao S, Liang T. Methods and compositions for inhibiting 5 alfa-reductasa activity. U S patent 5,605,909.1997.
45. Samman S, Sandstrom B, Toft MB, Bukhave K, Jensen M, Sorensen SS, et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr 2001;73:607-12.
46. Juhel C, Armand M, Pafumi Y, Rosier C, Vanermander J, Lairon D. Green tea extract inibits lipolysis of triglycerides in gastric and duodenal medium in vitro. J Nut Biochem 2000;11:45-51.
47. Godoy A, Recasens S, Serra M, Moix S. Utilización de terapias alternativas para el tratamiento de la obesidad [carta]. Med Clin (Barc) 1998;111:478-9.
48. Godoy A, Recasens S, Manresa JM, Vila J, Moix S. Hipertiroidismo yatrógene secundario a cápsulas adelgazantes. Factores predictivos para su detección precoz. An Med Interna (Madrid) 1998;15:245-9.
49. BOE 49/1997, 26 de febrero de 1997; p. 6435.
50. Andía Melero VM, Barragón Casas JM, Fraile Amador FJ, Arranz Martín A, López Guzmán-Guzmán A, Cuéllar Olmedo LA. Hecha la ley, hecha la trampa. Revista Formación Continuada en Nutrición y Obesidad 1998;1:315-6.
51. Oria Mundín EJ. Peligros de los fármacos milagrosos adelgazantes. Revista Formación Continuada en Nutrición y Obesidad 1998;1:270-9.
52. Chrispohervasey V. Las extraordinarias propiedades del suero láctico. CH- 1832. Chamby-Montrux 1993; p. 26-30.
53. Deuchi K, Kanauchi O, Imasato Y, Kobayashi E. Decreasing effect of chitosan on the apparent fat digestibility by rats fed on a high-fat diet. Compilation Copyright. Intelligent Health, 1996.
54. Deuchi K, Kanauchi O, Imasato Y, Kobayashi E. Increasing effect of chitosan d ascorbic acid mixture on fecal dietary fat excretion. Compilation Copyright. Intelligent Health, 1996.
55. Deuchi K, Kanauchi O, Imasato Y, Kobayashi E. Mechanism for the inhibition of fat digestion by chitosan and for the synergist effect of ascorbate. Bioscience Biotech, 1995;59:786-90.
56. Sugano M, Fujikawa T, Hiratsuji Y, Nakashima K, Fukuda N, Hasegawa Y. A novel use of chitosan as a hypocholesterolemic agent in rats. Am J Clin Nutr 1980;33:787-93.
57. Han Lk, Kimura Y, Ocuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes Relat Metab Disord 1999;23:174-9.
58. Veneroni G, Veneroni F, Contos S, Tripodi S, de Bernardi M, Guarino C, et al. Effect of a new chitosan dietary integrator and hipocaloric diet on hyperlipidemia and overweight in obese patient. Acta Toxicol Ther 1996;17:54-70
59. Colombo P, Sciutto AM. Nutricional aspects of chitosan employment in hipocaloric diet. Acta Toxicol Ther 1996;17:288-302.
60. Macchi G. A new approach to the treatment of obesity: chitosan' effect on body weight reduction and plasma cholesterol's levels. Acta Toxicol Ther 1996;17:304-20.
61. Gades MD, Stern JS. Chitosan supplementation does not affect fat absorption in realthy males fed a high-fat diet, a pilot study. Int J Obes 2002;26:119-22.
62. Guerciolini R, Radu-Radulescu L, Boldrin M, Dallas J, Moore R. Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res 2001;9:364-7.
63. Calderón Amigo J, Moreneo Mercer J, Calderón Gomez J, Cabo Soler JR. El test ALCAT de sensibilidad a los alimentos y su interés en medicina estética. Revista de la Sociedad Española de Medicina Estética 1996, 40:33-41.
64. Ho SC, Tai ES, Eng PH, Tan CE, Fok AC. In the absence of dietary surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. Singapore Med J 2001;42:6-10
65. Wuolijoki E, Hirvela T, Ylitalo P. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999;21:357-61.
66. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999;53:379-81
67. Rumpler W, Seale J, Clevidence B, Judd J, Wiley E, Yamamoto S, et al. Oolong tea increasees metabolic rate and fat oxidation in men. J Nutr 2001;131:2848-52
68. Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav 2000;71:87-94.
69. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Núnez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998;280:1596-600.
70. Vuksan V, Jenkis DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized centrelled metabolic trial. Diabetes Care 1999;22:913-9.
71. Vido L, Facchin P, Antonello I, Gobber D, Rigon F. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol 1993;28:133-6.
72. Cairella M, Marchini G. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter 1995;146:269-74.
73. Livieri C, Novazi F, Lorini R. The use of highly purified glucomannan-based fibers in childhood obesity. Pediatr Med Chir 1992;14:195-8.
74. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289-93.
75. Morán S, Uribe M, Prado ME, de la Mora G, Muñoz RM, Pérez MF, et al. Effects of fiber administration in the prevention of gallstones in obese patients on a reducing diet. A clinical trial. Rev Gastroenterol Mex 1997;62:266-72.
76. Enzi G, Inelmen EM, Crepaldi G. Effect of a hydrophilic mucilage in the treatment of obese patients. Pharmatherapeutica 1980;2:421-8.
77. Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Diet 2001;14:243-50.